Shop Antibodies
Best Seller

Biosimilar Antibody Production with Guaranteed Stability


Antibody: Monoclonal Antibody

Concentration: 1 mg/ml of purified IgG

Application: In vitro and In vivo

Reactivity: Human

BiCell Scientific Inc has developed a robust recombinant expression system to produce human biosimilar antibodies in lentivirus transfected B cell hybridomas.

BiCell Scientific Inc’s Biosimilar Antibodies are research-grade human biosimilar monoclonal antibodies. Each biosimilar antibody is produced using recombinant technology in bioreactors and incorporates the same variable region sequence as the original pharmaceutical substance. The Fc domain is offered in four different isotypes: IgG1, IgG2, IgG3 and IgG4.

Biosimilar antibodies make it possible to study the biological effects of a pharmaceutical substance without needing to source expensive pharmaceutical-grade therapeutics. They can be used for many research applications including functional assays, flow cytometry, ELISA, Immunohistochemistry, pharmacokinetic assays, and others.

BiCell Scientific Inc has optimized hybridoma cell growth for monoclonal antibody secretion in continuous cultivation bioreactor with a chemically defined, serum-free culture medium (Cat No: BCMABK6). Continuous cultivation bioreactor permits monoclonal antibody secretion rate to reach 100-150 μg/ml medium, which enables BiCell Scientific Inc to deliver biosimilar antibodies at the gram level.

BiCell Scientific has found that an equal number of light chain to heavy chain is essential for correct folding of heavy chain and secretion of antibody with thermal stability. BiCell Scientific’s recombinant antibody production service harnesses the advantageous lentiviral transduction ability to simultaneously express IgG heavy chain and light chain at a molecular ratio of 1:1 in naive B cell hybridomas. The resultant B cell hybridomas can produce recombinant antibodies at a similar level to native B cell-myeloma fused hybridomas. The resultant recombinant antibodies undergo similar assembly and modification processes to native antibodies in the endoplasmic reticulum, that is crucial to obtain antibody preparations with low contents of aggregates.

  • Gene synthesis of therapeutic antibody heavy chain and light chain sequences from NCBI database
  • Molecular cloning of antibody heavy chain and light chain sequences into lentiviral backbone vector
  • Transfection of HEK293T cells with lentiviral backbone vector as well as vectors expressing gagpol, rev and vsvg
  • Harvesting and purification of lentivirus from cell culture medium
  • Transducing naive Sp2/0-Ag14 hybridoma cells
  • Clonal selection and stable cell line establishment in 96-well plate
  • Validation of recombinant antibody expression in 96-well plate and selection of highly expressing clones
  • Clonal expansion and affinity purification of recombinant antibody


For Research Use Only. Not for use in clinical diagnostics or therapeutics.

Customers will receive the following deliverables at the end of each project:

  • One stable Sp2/0-Ag14 hybridoma cell line expressing recombinant biosimilar monoclonal antibody with the highest yield
  • 1 mg to 1 g of affinity column purified biosimilar monoclonal antibody
  • Biosimilar IgG heavy chain and light chain cloning into lentiviral vector – 2-3 weeks
  • Lentivirus packaging for biosimilar IgG molecule  – 1-2 weeks
  • Naive Sp2/0-Ag14 hybridoma cell transduction – 1-2 weeks
  • Clonal selection and stable cell line establishment – 3-4 weeks
  • Recombinant antibody expression validation – 2-3 weeks
  • Cell culture expansion and affinity purification – 2-3 weeks

Additional information

Antibody Production Scale

1 mg, 5 mg, 10 mg, 100 mg, 1 g


IgG1, IgG2, IgG3, IgG4


There are no reviews yet.

Be the first to review “Biosimilar Antibody Production with Guaranteed Stability”

"I am really impressed with your approach. We tried multiple times previously to create monoclonal and polyclonal antibodies to claudin-2 and MLCK1. We have had limited success generating polyclonals and no success generating monoclonals. You have generated outstanding monoclonals to both. I look forward to continuing to work with you."

Jerrold R. Turner, M.D., Ph.D.

Brigham and Women’s Hospital | Harvard Medical School

"The polyclonal antibody you generated for KIAA0408 is stunning! KIAA0408 is a novel cilium molecule that has never been studied. So, clearly there will be a lot of demand for it as we have discovered a very interesting finding and the story will be published in a high impact journal. I am strongly inclined to generate monoclonal antibody for this protein too and we should think about patenting it."

Univ.-Prof. Jay Gopalakrishnan PhD

Heinrich-Heine-Universität | Universitätsklinikum Düsseldorf

"Your ARL13B antibody works beautifully!!! We’re so happy to have a cilia-specific antibody made in rat! I can send you high resolution images to be posted on your website."

Julie Craft Van De Weghe, PhD

School of Medicine | University of Washington

"The assay is a homophilic interaction mediated cell adhesion on purified protein (in this case, immobilized purified Pcdhga9 to Pcdhga9 expressed on cell surface). Compared to control, cell adhesion is reduced in the presence of Pcdhga9 monoclonal antibody supernatants!"

Divyesh Joshi, PhD

School of Medicine | Yale University

"The rabbit hybridoma supernatants of anti-APOBEC3 project are tested positive by ELISA, and we are very happy about it! We previously tried a company, Abclone. Their Project "A" has immune response that is <10,000 titer in antiserum, which would explain why there is no positive mAb after fusion. Their project "B" didn't have any immune response in rabbit."

Harshita B Gupta, PhD.

School of Medicine | UT Health San Antonio

"We have tested anti mouse T cell antiserum samples from both rabbits you sent to us.

They worked very well! Thank you!"

Victoria Gorbacheva, PhD.

School of Medicine | Cleveland Clinic

Contact us for questions or custom requests!